X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
EU WC
0
Listed Suppliers
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
ANT01 (pipamperone dihydrochlorideshows) a unique combined high BLOCKING affinity toward the human serotonin 2A and dopamine 4 receptor, which being invetigated for for Major Depressive Disorder.
Lead Product(s): Pipamperone
Therapeutic Area: Psychiatry/Psychology Product Name: ANT-01
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 05, 2023
Details:
The data for ANT-01 (pipamperone dihydrochloride) showed an improvement in the ability to feel pleasure and in cognitive function, which has not been demonstrated by any other antidepressant molecule.
Lead Product(s): Pipamperone,Undisclosed
Therapeutic Area: Psychiatry/Psychology Product Name: ANT-01
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Johnson & Johnson
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 05, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
